Mariner Independent Advisor Network’s Iovance Biotherapeutics IOVA Stock Holding History

Mariner Independent Advisor Network’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$300K	Buy	+31,300	New	+$361K	0.01%	523

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Mariner Independent Advisor Network's IOVA Position: Q3 2022 in Review

Mariner Independent Advisor Network opened a new position in Iovance Biotherapeutics (IOVA) in Q3 2022: 31,300 shares worth $300K. The stake represents 0.01% of the portfolio and ranks #523 among its holdings.

242 funds tracked by Wall St. Rank hold IOVA as of Q3 2022.

Mariner Independent Advisor Network held 31,300 shares of Iovance Biotherapeutics worth $300K as of Q3 2022.
Iovance Biotherapeutics was a new Mariner Independent Advisor Network position in Q3 2022.
Iovance Biotherapeutics made up 0.01% of Mariner Independent Advisor Network's portfolio in Q3 2022, its #523 holding.
242 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2022.

Based on Mariner Independent Advisor Network's 13F filing for Q3 2022, filed 10 Nov 2022.